InMed PharmaceuticalsINM -0.61%29 PB Ratio is 0.79 as of Jul. 10, 2026, which is 139% above its 10-year median of 0.33. GuruFocus rates INM with a GF Score™ of 29/100 and a GF Value™ of $0.93 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 919 Drug Manufacturers companies, InMed Pharmaceuticals ranks better than 83.68% on this metric.
InMed Pharmaceuticals Inc stock PB Ratio (=0.79) is close to 3-year high of 0.83.
The historical rank and industry rank for InMed Pharmaceuticals's PB Ratio or its related term are showing as below:
INM'
s PB Ratio Range Over the Past 10 Years
Min: 0.11 Med: 0.33 Max: 1.29
Current: 0.79
During the past 13 years, InMed Pharmaceuticals's highest PB Ratio was 1.29. The lowest was 0.11. And the median was 0.33.
INM's PB Ratio is ranked better than 83.68% of 919
companies
in the Drug Manufacturers industry
Industry Median: 1.9
vs INM: 0.79
During the past 12 months, InMed Pharmaceuticals's average Book Value Per Share Growth Rate was -64.20% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -71.00% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -61.10% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -30.90% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of InMed Pharmaceuticals was 496.90% per year. The lowest was -71.00% per year. And the median was -18.45% per year.
Back to Basics: PB Ratio
InMed Pharmaceuticals (NAS:INM) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, InMed Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InMed Pharmaceuticals PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, InMed Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where InMed Pharmaceuticals's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
InMed Pharmaceuticals (INM) has a PB Ratio of 0.79 as of Jul. 10, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on InMed Pharmaceuticals and its competitors. This is 139% above median its historical median of 0.33. Over the past decade, InMed Pharmaceuticals' PB Ratio has ranged from 0.11 to 1.29. According to the industry distribution chart, InMed Pharmaceuticals ranks #150 out of 919 companies in the Drug Manufacturers industry, placing it in the top 16.3%.
Is InMed Pharmaceuticals' PB Ratio too high?
InMed Pharmaceuticals' current PB Ratio of 0.79 is 139% above median its 10-year median of 0.33. Over the past 10 years, this metric has ranged from a low of 0.11 to a high of 1.29. The Drug Manufacturers industry median PB Ratio is 1.90. InMed Pharmaceuticals' value of 0.79 is 58.4% below this industry median. Based on the distribution chart, InMed Pharmaceuticals ranks #150 out of 919 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, InMed Pharmaceuticals has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does InMed Pharmaceuticals' PB Ratio compare to SNOA and CVSI?
According to the Drug Manufacturers industry distribution chart, InMed Pharmaceuticals ranks #150 out of 919 companies for PB Ratio. This places InMed Pharmaceuticals in the top 16% of its industry — outperforming the majority of peers. The industry median PB Ratio is 1.90. InMed Pharmaceuticals' value of 0.79 is 58.4% below this benchmark. Historically, InMed Pharmaceuticals' own PB Ratio has ranged from 0.11 to 1.29 over the past decade. While the company's 10-year median is 0.33 vs. the industry median of 1.90, InMed Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.90, based on 919 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. InMed Pharmaceuticals's current PB Ratio of 0.79 is 58.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on InMed Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InMed Pharmaceuticals's current PB Ratio is 0.79, which is 139% above median its own 10-year median of 0.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InMed Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, InMed Pharmaceuticals (INM) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.93, compared to a current price of $1.65 — trading 77.4% above its estimated fair value. The current PB Ratio is 0.79, which is 139% above median its 10-year median of 0.33 and 58.4% below the Drug Manufacturers industry median of 1.90. InMed Pharmaceuticals' overall GF Score™ is 29/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For InMed Pharmaceuticals (INM), the current PB Ratio is 0.79 as of Jul. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InMed Pharmaceuticals (INM) Overvalued in 2026?
Based on GuruFocus' analysis, InMed Pharmaceuticals stock appears to be overvalued.
The current stock price of $1.65 is trading 77.4% above its estimated GF Value™ of $0.93.
GuruFocus considers InMed Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for INM:
PB Ratio: 0.79 (139% above median its 10-year median of 0.33)
GF Value™: $0.93 vs. price of $1.65 (77.4% above fair value)
Industry Position: 58.4% below the Drug Manufacturers median (#150 of 919)
No single metric tells the full story. See the INM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InMed Pharmaceuticals Inc is a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors. The company's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications.
29GF Score
Get the complete analysis for INM
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INM has been successfully added to your 
